- Eli Lilly, headquartered in Indianapolis, Indiana, is a leading pharmaceutical company specializing in diabetes and obesity treatments, with significant market momentum driven by its GLP-1 products like Mounjaro and Zepbound.
- In April 2026, Lilly announced plans to acquire CAR-T firm Kelonia for up to $7 billion, leveraging its successful tirzepatide product to fuel further growth, while also launching its oral GLP-1 pill, Foundayo, approved by the FDA on April 1, 2026.
- Lilly's key customers include healthcare providers and patients in the diabetes and obesity markets, with partnerships likely extending to healthcare systems and pharmacy benefit managers to enhance drug accessibility.
- The ideal buyer for Lilly's products includes healthcare providers looking to address obesity and diabetes management, as Lilly's innovative therapies offer significant benefits in chronic weight management and metabolic health, making them critical in today's healthcare landscape.
Eli Lilly's workforce is organized across six departments, with a total headcount of 47,000 employees. The largest department is Information Technology, which comprises three employees, followed by Health Services, Engineering, Community and Social Services, Operations, and Other, each contributing one employee. This distribution indicates a significant emphasis on specialized roles within a compact departmental structure, highlighting a focused operational strategy.
The company's workforce is primarily concentrated in two locations, with Plainville, CT and Phoenix, AZ each accounting for one employee. The majority of employees, categorized under 'Other,' are distributed across nine additional locations, suggesting a decentralized operational model. This geographic distribution reflects a strategic approach to workforce management, allowing for flexibility and regional adaptability.
